Thrita

Published by: Kowsar

Preliminary Evidence-Based Pharmacotherapy of Mitoxantrone for Multiple Sclerosis in an Iranian Population

Zahra Tolou-Ghamari 1 , *
Author Information
1 Isfahan Neurosciences Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Thrita: September 01, 2015, 4 (3); e28644
  • Published Online: September 6, 2015
  • Article Type: Research Article
  • Received: March 14, 2015
  • Revised: April 26, 2015
  • Accepted: May 17, 2015
  • DOI: 10.5812/thrita.28644

To Cite: Tolou-Ghamari Z. Preliminary Evidence-Based Pharmacotherapy of Mitoxantrone for Multiple Sclerosis in an Iranian Population, Thrita. 2015 ;4(3):e28644. doi: 10.5812/thrita.28644.

Abstract
Copyright © 2015, Thrita. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009; 78(9): 1083-94[DOI][PubMed]
  • 2. Burns SA, Lee Archer R, Chavis JA, Tull CA, Hensley LL, Drew PD. Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. Brain Res. 2012; 1473: 236-41[DOI][PubMed]
  • 3. Rommer PS, Stuve O. Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects. Curr Treat Options Neurol. 2013; 15(3): 241-58[DOI][PubMed]
  • 4. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013; 5[DOI][PubMed]
  • 5. Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: why? When? How? CNS Drugs. 2013; 27(6): 403-9[DOI][PubMed]
  • 6. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004; 18(6): 379-96[PubMed]
  • 7. Chan A, Lo-Coco F. Mitoxantrone-related acute leukemia in MS: an open or closed book? Neurology. 2013; 80(16): 1529-33[DOI][PubMed]
  • 8. Hofmann A, Stellmann JP, Kasper J, Ufer F, Elias WG, Pauly I, et al. Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients. Mult Scler. 2013; 19(7): 920-5[DOI][PubMed]
  • 9. Lee CK, Gebski VJ, Coates AS, Veillard AS, Harvey V, Tattersall MH, et al. Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. Springerplus. 2013; 2: 391[DOI][PubMed]
  • 10. Durrieu G, Mazau B, Jegu J, Lapeyre-Mestre M, Delord JP, Montastruc JL, et al. Drugs and cancer: an analysis of the French Pharmacovigilance Database. Therapie. 2013; 68(3): 149-54[DOI][PubMed]
  • 11. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick AD, Dahlgren L, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013; 13(3): 251-60[DOI][PubMed]
  • 12. Rossato LG, Costa VM, Dallegrave E, Arbo M, Dinis-Oliveira RJ, Santos-Silva A, et al. Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study. Basic Clin Pharmacol Toxicol. 2014; 114(3): 254-62[DOI][PubMed]
  • 13. Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol. 2014; 175(3): 397-407[DOI][PubMed]
  • 14. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013; 6[DOI][PubMed]
  • 15. Hamzehloo A, Etemadifar M. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Arch Iran Med. 2007; 10(1): 59-64[PubMed]
  • 16. Hamzehloo A, Etemadifar M. Early onset cardiotoxicity associated with mitoxantrone in patients with multiple sclerosis. Neurosciences (Riyadh). 2006; 11(3): 221-2[PubMed]
  • 17. An G, Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. AAPS J. 2012; 14(2): 352-64[DOI][PubMed]
  • 18. Patel KJ, Tredan O, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol. 2013; 72(1): 127-38[DOI][PubMed]
  • 19. Tolou-Ghamari Z, Shaygannejad V, Ashtari F. Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital. Int J Prev Med. 2013; 4-8[PubMed]
  • 20. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in patients. Cancer Treat Rev. 1983; 10 Suppl B: 23-7[DOI][PubMed]
  • 21. Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs. 1985; 3(2): 109-16[PubMed]
  • 22. Tolou Ghamari Z, Mehavari Habibabadi J, Palizban AA. Evidence-Based Pharmacotherapy of Epilepsy. Arch Neurosci. 2014; 2(2)[DOI]
  • 23. Shaygannejad V, Tolou-Ghamari Z. What is the Real Fate of Vitamin D in Multiple Sclerosis? Int J Prev Med. 2013; 4-64[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments